Ozempic face: what is it and how can you prevent a gaunt appearance when taking GLP-1 medication?

Short answer: ‘Ozempic face’ is the colloquial term for a gaunt appearance following rapid weight loss with GLP-1 drugs. It results from the loss of facial fat and is not a recognised side effect, but rather an aesthetic effect that can be minimised through a gradual weight-gain programme.

‘Ozempic face’ is the popular term for a sunken, aged appearance in the face following rapid weight loss with GLP-1 medicines such as Ozempic, Wegovy, Mounjaro and Saxenda. Holler cheeks, deeper wrinkles around the mouth and a loss of youthful volume: these are recognisable signs that many users see appearing online. But what actually happens to the face during weight loss, why do some people experience this whilst others do not, and what can you do about it yourself? This blog post provides an honest, medically substantiated answer.

What exactly is the ‘Ozempic face’?

The ‘Ozempic face’ is not an official medical term or a recognised side effect of semaglutide, but rather a collective term that has emerged on social media. The term describes facial changes resulting from significant fat loss in the face: sunken cheeks, deeper creases around the nose and mouth, and a loss of the youthful volume that makes the face look plump and relaxed.

A recent literature review describes that these changes are linked to a loss of facial volume and thinner skin resulting from reduced collagen production, particularly following rapid and significant weight loss. The term itself does not originate from clinical research, but the underlying mechanisms are very well described in the scientific literature. This distinction is important: the phenomenon is real; the term is one that has become established in popular usage.

What causes a sunken face following weight loss?

A sunken face occurs because the face contains a relatively large amount of subcutaneous fat, particularly in the cheeks and around the eyes. During rapid weight loss, this fat disappears, whilst the skin does not always shrink at the same rate.

Research into tissue changes following weight loss shows that the skin’s elasticity is a crucial factor: the less elastic the skin is, the greater the risk of visible sagging following a loss of volume. This applies particularly to older users, as the skin’s elasticity and collagen production naturally decline with age. It is important to note that this is not an effect unique to GLP-1 medicines, but a well-known consequence of rapid weight loss in general. Doctors observe the same pattern even following gastric bypass surgery or extreme diets.

Does this apply to all GLP-1 medicines: Ozempic, Wegovy, Mounjaro and Saxenda?

Yes, the risk depends on the amount and rate of weight loss, not on the specific molecule. Semaglutide, the active ingredient in Ozempic (semaglutide), Wegovy and Rybelsus; tirzepatide in Mounjaro (tirzepatide) and Zepbound; and liraglutide in Saxenda (liraglutide) can all produce this potential effect in the event of significant weight loss.

A network meta-analysis of body composition shows that tirzepatide, on average, results in slightly greater weight loss than semaglutide, which could theoretically have a greater effect on facial volume during rapid weight loss. Liraglutide, with its more gradual action profile due to daily dosing, usually exhibits a similar pattern, linked to overall weight loss. It is therefore not a question of which medicine you use, but of how much and how quickly you lose weight.

Who is most at risk of developing ‘Ozempic face’?

People who lose a significant amount of weight in a short space of time – for example, more than one per cent of their body weight per week – are at the greatest risk of visible volume loss in the face. Older users naturally have less skin elasticity and collagen, which means the skin does not keep up as well when the fat disappears.

Smoking accelerates skin ageing and further reduces elasticity, thereby increasing the risk even further. People who naturally have little facial fat also notice the loss of volume sooner, as they have less of a ‘buffer zone’. According to Farmacotherapeutisch Kompas, a gradual dose increase is specifically intended to regulate the rate of weight loss, which indirectly also limits this risk.

How can a sunken face be prevented or minimised?

A gradual increase in dosage is the first and most important measure, and this is precisely what the standard dosing regimen for GLP-1 medicines is already designed to achieve. A slower start gives the body and the skin more time to adapt to the change in volume.

In addition, adequate protein intake during GLP-1 treatment is important, in combination with strength training to preserve muscle mass, including in the jaw and neck regions. Research into muscle mass loss during GLP-1 therapy shows that targeted strategies, such as protein intake, can limit the loss of lean body mass. A study on strength training during incretin-based treatment confirms that resistance training has a positive effect on changes in body composition. Adequate fluid intake and basic skincare using sun protection factor (SPF) and, where appropriate, retinoids can support skin quality, although this is general advice with no guaranteed effect on facial volume. Always discuss any concerns about the rate of your weight loss with your treating doctor or coach.

Is a sunken face reversible?

Partially: facial volume may partially return once your weight has stabilised, but the skin’s elasticity recovers considerably more slowly than fatty tissue. Once your weight has stabilised, the body gradually builds up a small amount of fat again, including in the face, which can compensate for some of the lost volume.

For people who still experience problems with sagging skin after their weight has stabilised, there are cosmetic options such as dermal fillers. We mention this here for information purposes only: Goodweigh does not recommend this and does not offer it as a service in its own right. Such a procedure is an individual, cosmetic choice that you should discuss with a qualified specialist, regardless of your GLP-1 treatment.

The ‘Ozempic face’ in perspective

A sunken face is a possible aesthetic effect of rapid weight loss, not a dangerous side effect. It is no reason to stop an effective treatment, but it is a reason to consciously monitor the rate of weight loss. With a gradual weight-loss plan, sufficient protein and coaching to monitor the pace of your weight loss, the risk can be significantly reduced. Would you like to know what a realistic weight loss means for you specifically? Read more about how much weight you can lose with Ozempic and book your initial consultation today for personalised guidance.